Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department plans to extend the availability of Evusheld as a covid-19 prophylactic treatment through clinical trials for immunocompromised individuals.

The Department’s clinical advisors have recommended that a clinical trial of Evusheld should be considered to understand the connection between in vitro tests and clinical outcomes for current and future variants and evaluate the effectiveness and safety of a dose of 600 milligrams, which was not tested in randomised controlled trials. We are currently exploring options for such a trial.